Work

Leprosy post-exposure prophylaxis risks not adequately assessed – Author's reply

Year: 2021

Type: letter

Abstract: We thank Diana Lockwood and colleagues for their concerns about leprosy post-exposure chemoprophylaxis with single-dose rifampicin (SDR-PEP) for contacts of people diagnosed with leprosy.1 Some of their concerns against SDR-PEP are based on misunderstandings of the outcome of the COLEP trial.

Source: The Lancet Global Health

DOI: 10.1016/s2214-109x(21)00047-4

Authors: Jan Hendrik Richardus, Liesbeth Mieras, Paul Saunderson, Eliane Ignotti, Marcos Virmond, Mohammad A Arif, Basu Dev Pandey, Arielle Cavaliero, Peter Steinmann

Institutions: Erasmus MC, Netherlands Aerospace Centre, Netherlands Leprosy Relief, American Leprosy Missions, Universidade do Estado de Mato Grosso, Instituto Lauro de Souza Lima, Ministry of Health and Population, Novartis Foundation, Swiss Tropical and Public Health Institute, University of Basel

Language: English

Topic: Leprosy Research and Treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,000

OpenAlex ID: W3138960923

Cites: 10

Cited by: 5

Related to: 10